BATRAFEN ® Ciclopirox

BATRAFEN ® is a drug based on Ciclopirox

THERAPEUTIC GROUP: Antimycotics for topical use

IndicationsAction mechanismStudies and clinical effectiveness Usage and dosage instructionsWarnings Pregnancy and lactationInteractionsContraindicationsUndesirable effects

Directions BATRAFEN ® Ciclopirox

BATRAFEN ® is indicated in the treatment of cutaneous mycoses sustained by fungi sensitive to Ciclopirox.

The enamel form is also indicated in the treatment of onychomycosis.

Mechanism of action BATRAFEN ® Ciclopirox

BATRAFEN ® is a drug based on Ciclopirox, an active ingredient with broad-spectrum and antibacterial antifungal activity and therefore used successfully in the treatment of dermatomycoses and onychomycoses.

Applied topically, the drug concentrates at the skin level where it performs its therapeutic activity by chelating different ions, including iron, thus removing them from the fungal metabolism and inevitably compromising its metabolic and reproductive capacities.

All this materializes in the static and fungicidal fungi action, which guarantees a prompt remission of the complained symptomatology.

Several studies have also attributed an anti-inflammatory potential to this active ingredient, which could prove to be important in the management of the disease.

Studies carried out and clinical efficacy

THE CYCLOPIROX IN THE TREATMENT OF THE ONICOMICOS OF THE ALLUCE

An Bras Dermatol. 2012 Jan-Feb; 87 (1): 19-25.

Study that, re-evaluating the different dosage schemes suggested during onychomycosis, reaffirms the clinical efficacy of Ciclopirox in the treatment of onychomycosis of the big toe

PHARMACOCINETIC CHARACTERISTICS OF CICLOPIROX-BASED ENAMEL

J Eur Acad Dermatol Venereol. 2013 Feb; 27 (2): e153-8. doi: 10.1111 / j.1468-3083.2012.04529.x. Epub 2012 Mar 26.

Interesting study that evaluates the penetration capacity of cyclopiroxil in nails, considering the use of innovative pharmacological formats.

CYCLOPIROX AS AN ANTICANCER POTENTIAL

J Clin Pharm Ther. 2011 Apr; 36 (2): 128-34. doi: 10.1111 / j.1365-2710.2010.01172.x. Epub 2010 Aug 24.

Recent study that reaffirms the efficacy of Ciclopirox systemically as a potential anticancer agent especially in the treatment of hematological malignancies.

Method of use and dosage

BATRAFEN ®

Cream, gel, cutaneous solution and skin powder at 1% of Ciclopirox;

8% Ciclopirox nail polish.

Generally we recommend applying the appropriate amount of cream, skin solution or skin powder 2-3 times a day directly on the region affected by the infectious process, until complete remission of symptoms.

It is generally recommended to extend the application of the drug for another 2 weeks after remission of symptoms.

The correct use of the enamel instead involves the application of the product on the affected nail, previously cleansed and cleaned from the hyperkeratotic layers, once a day, until the remission of the symptoms.

Warnings BATRAFEN ® Ciclopirox

Although the use of BATRAFEN ® is generally safe and has no clinically relevant side effects, the application of this medicine should be accompanied by compliance with different sanitary regulations useful for optimizing the therapeutic efficacy of the treatment and limiting the potential effects side.

The appropriate cleansing of the cutaneous region to be treated and of the hands following the application of the product, would in fact allow to avoid the dispersion of the drug, thus limiting the onset of resistant strains.

The patient receiving BATRAFEN ® should avoid direct exposure to ultraviolet radiation, given the phototoxic potential of the active ingredient.

Prolonged use of Ciclopirox could cause the onset of hypersensitivity reactions to the drug.

PREGNANCY AND BREASTFEEDING

The use of BATRAFEN ® during pregnancy and in the subsequent period of breastfeeding should be defined by the doctor based on the patient's clinical needs and supervised throughout the treatment.